Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Sunday, AstraZeneca's DATROWAY Shows Over 55% Response Rate In First-Line Advanced NSCLC In TROPION-Lung02 Phase 1b Trial With Immunotherapy Combinations

Author: Benzinga Newsdesk | June 02, 2025 02:27am
  • TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca's DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC
  • TROPION-Lung02 results include first exploratory QCS analysis of DATROWAY in first-line setting
  • NeoCOAST-2 phase 2 results continue to show potential for DATROWAY plus durvalumab and single-agent platinum chemotherapy in neoadjuvant setting

Posted In: AZN DSNKY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist